PRECIGEN, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
PRECIGEN, INC. (PGEN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-25
- PRECIGEN, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.63M, a 389.79% increase from fiscal 2024.
- PRECIGEN, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $333.00K, a 2.78% increase from fiscal 2023.
- PRECIGEN, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $324.00K.
- PRECIGEN, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $1.63M 10-K · filed 2026-03-25 |
| 2024-12-31 | $333.00K 10-K · filed 2026-03-25 |
| 2023-12-31 | $324.00K 10-K · filed 2026-03-25 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
| 2014-12-31 | $677.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $527.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $527.00K 10-K · filed 2015-03-02 |
| 2011-12-31 | $71.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |